New Antivirals Show Promise for an Interferon-free Hepatitis C Treatment

Atif Zaman, MD, MPH


Journal Watch 

In This Article


These findings provide early evidence that the next generation of DAAs is more potent than the current generation in treating HCV genotype 1 infection. In this cohort of the most difficult-to-treat HCV patients — previous null responders with genotype 1 infection — a 24-week SVR of 90% was achieved after 24 weeks of quadruple therapy (2 DAAs and PEG/RBV). Even an interferon-free regimen of the 2 DAAs resulted in an SVR of 36%. Results are eagerly anticipated from the phase III trial currently under way.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.